Update on Crohn’s disease and ulcerative colitis

References

• Rajca S, Grondin V, Louis E et al. Crohn’s disease-associated dysbiosis as a predictive factor of clinical relapse: a microbiological substudy of the GETAID-STORI cohort. J. Crohns Colitis5, S4 (2011).
   Google Scholar
• Rajca S, Duboc H, Sokol H et al. Dysbiosis in inflammatory bowel disease: a link with antimicrobial peptides secretion? J. Crohns Colitis5, S164 (2011).
   Google Scholar
• Machiels K, Joossens M, De Preter V et al. Faecalibacterium prausnitzii is also reduced in ulcerative colitis. J. Crohns Colitis5, S166 (2011).
   Google Scholar
• Wildenberg ME, Vos ACW, Duijvestein M et al. Autophagy contributes to immune regulation through destabilization of the immunological synapse. J. Crohns Colitis5, S3 (2011).
   Google Scholar
• Cleynen I, Artieda M, Verspaget HW et al. Role of the CYLD protease gene in Crohn’s disease, independent from its neighbouring gene CARD15. J. Crohns Colitis5, S160 (2011).
   Google Scholar
• Lee JC, Lyons P, McKinney E et al. Gene expression profiling in CD8 T cells predicts disease course in Crohn’s disease and ulcerative colitis. J. Crohns Colitis5, S3 (2011).
   Google Scholar
• Burger DC, Thomas SJ, Walsh AJ et al. Depth of remission may not predict outcome of UC over 2 years. J. Crohns Colitis5, S4–S5 (2011).
   Google Scholar
• Bojic D, Bojic B, Protic M et al. Fecal calprotectin is reliable surrogate marker of endoscopic and histologic mucosal healing in Crohn’s disease and ulcerative colitis. J. Crohns Colitis5, S34 (2011).
   PubMedGoogle Scholar
• Manosa M, Garcia Planella E, Gordillo J et al. Usefulness of faecal calprotectin to detect postoperative endoscopic recurrence in Crohn’s disease. J. Crohns Colitis5, S51 (2011).
   Google Scholar
• Algaba A, Linares PM, Fernández-Contreras ME et al. Relation between endoscopic and histological activity of the intestinal inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors. J. Crohns Colitis5, S32 (2011).
   Google Scholar
• Drobne D, Bossuyt P, Breynaert C et al. Long term evolution and impact of immunomodulator co-treatment and withdrawal on infliximab trough levels in 223 patients with Crohn’s disease. J. Crohns Colitis5, S10–S11 (2011).
   Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med.362, 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J. Crohns Colitis5, S8 (2011).
   Google Scholar
• Vermeire S, Colombel J, Robinson AM et al. Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn’s disease patients stratified by prior anti-TNF use. J. Crohns Colitis5, S68–S69 (2011).
   Google Scholar
• Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. J. Crohns Colitis5, S8 (2011).
   Google Scholar
• Ferrante M, Ballet V, Geskens V et al. Infliximab for severe IV steroid-refractory ulcerative colitis: can infliximab trough levels guide our management? J. Crohns Colitis5, S9 (2011).
   Google Scholar
• Reinisch W, Sandborn WJ, Kumar A et al. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. J. Crohns Colitis5, S10 (2011).
   Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. J. Crohns Colitis5, S68 (2011).
   Google Scholar
• Büning J, Schmidt K, Fellermann K et al. Tacrolimus treatment in ulcerative colitis: a three center experience. J. Crohns Colitis5, S76 (2011).
   Google Scholar
• Vandepapeliere P, Malan F, Rogler G et al. Phase I–II safety, immunogenicity and clinical results of TNF-α-kinoid immunotherapeutic immunization in Crohn’s disease patients. J. Crohns Colitis5, S6–S7 (2011).
   Google Scholar
• Hueber W, Sands BE, Vandemeulebroecke M et al. Inhibition of IL-17A by secukinumab is ineffective for Crohn’s disease (CD). J. Crohns Colitis5, S7 (2011).
   Google Scholar
• Pariente B, Mocan I, Camus M et al. NKG2D activation drives Th17 response in Crohn’s disease. J. Crohns Colitis5, S7–S8 (2011).
   Google Scholar
• Lutgens M, Siersema PD, Vleggaar F et al. Risk factors for inflammatory bowel disease associated colorectal carcinoma. J. Crohns Colitis5, S12 (2011).
   Google Scholar
• Gordillo J, Domènech E, Panés J et al. Incidence of dysplasia and colorectal cancer in patients with ulcerative colitis included in the Spanish ENEIDA registry. J. Crohns Colitis5, S11 (2011).
   Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology130, 1030–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Risk of squamous and basal cell carcinomas in patients with inflammatory bowel disorders exposed to thiopurines: the CESAME National Cohort Study. J. Crohns Colitis5, S9–S10 (2011).
   Google Scholar